Solid Biosciences (SLDB)
(Real Time Quote from BATS)
$5.36 USD
-0.08 (-1.47%)
Updated Sep 19, 2025 11:00 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLDB 5.36 -0.08(-1.47%)
Will SLDB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SLDB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLDB
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
SLDB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Other News for SLDB
Is SLDB preparing to trend lower? 20 Day Moving Average Resistance shows up after declining 0.55%
Is SLDB likely to continue lower? 20 Day Moving Average Resistance shows up after gaining 1.11%
H.C. Wainwright Remains a Buy on Solid Biosciences (SLDB)
Is SLDB poised for gains? MACD Bullish Signal Line Cross shows up after declining 1.46%
Directional Movement Crossover Bullish appears for SLDB after 1.86% move